A Study of Galunisertib in Participants With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of the study drug known as
galunisertib in participants with myelodysplastic syndromes (MDS). Participants with
different degrees of disease (very low, low, and intermediate risk) will be studied. The
study treatment is expected to last about 6 months for each participant.